Allos Therapeutics has announced on Wednesday morning that they will be expanding the share offerings and will now sell around 14 million shares for $7.10 per share. On Monday, Allos Therapeutics has already announced that …

Allos Therapeutics Inc (Nasdaq:ALTH) must be delighted with joy after getting a green signal by the FDA panel for their injectable drug Folotyn, which will be used for the treatment of peripheral T-cell lymphoma, a rare …